Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors.
Eszter Anna JankaImre Lőrinc SzabóSándor KollárTünde Toka-FarkasBeatrix VányaiTünde VárvölgyiAnikó KapitányHibah ShabuAndrea SzegediGabriella EmriPublished in: Cancers (2024)
Baseline M stage and serum S100B appear to be independent prognostic factors for both PFS and OS in melanoma patients treated with BRAF + MEK inhibitors. We newly identified significant and independent prognostic effects of primary tumor localization and Clark level on survival that warrant further investigation.